Search Results 481-490 of 15860 for pharmacogenetics
Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure, one of the world's most[...] ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Mayo Clinic neurology experts are presenting research findings on Parkinson's disease, Alzheimer's disease, sleep disorders, concussions, multiple sclerosis and ...
... . ART-20051269. Home; Subscription Confirmation. Final days of 5X Challenge! 5X My Gift! The challenge ends 10/10. Your gift today can have 5X the ...
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products ...
Scottsdale/Phoenix, Ariz. This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast ...
The purpose of this study is to develop an AI-driven biomarker based on FDG-PET images to track longitudinal brain changes in asymptomatic (n = 15) and ...
About this study · characterize their risk for developing T1D and identify subjects eligible for prevention trials; · describe the pathogenic evolution of T1D; ...
Share · Tweet. See also. Abdominal aortic aneurysm · Acne · Actinic keratosis · Atrial septal defect (ASD) · Autoimmune pancreatitis · Back pain ...
The Pharmacology Shared Resource provides preclinical and clinical pharmacokinetic, pharmacodynamic and pharmacogenetic expertise, methodologies and ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The challenge ends 10/10. Your gift today can have 5X the impact on AI research and technology.